Pharma industry groups are sounding the alarm, warning that President Donald Trump’s tariffs could worsen drug shortages, ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

While sentencing a Sarnia man to two years in jail for trafficking crystal meth, the judge noted the drug doesn’t kill people ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

drug prices, and what’s ahead for Johnson & Johnson. This interview has been condensed and edited for clarity. You've had some structural changes and spun out the consumer business. Has that ...

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront ...